CRL · Full Picture

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — the full picture

Earnings window · 2026-07-15 to 2026-08-10 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Income Tax Rate Changes · TaxPriority 83
    -9.2% net_income (realized); 3 sources (press_release, sec_filing, transcript); 3 forward row(s); structured_verified
    Provision for income taxes for the three months ended June 27, 2026: $53.93 million; income before income taxes: $53.17 million; effective tax rate: 101.4% compared to 26.2% in the prior-year period.
  2. Liquidity and Debt Position · Debt, leverage & refinancingPriority 78
    -8.3% liability (realized); 3 sources (press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    As of June 27, 2026, $105.0 million of deferred consideration for the Cambodian NHP Supplier acquisition remains to be paid and is recorded in Accrued liabilities.
  3. Capital Return Program · Buybacks & dividendsPriority 76
    -8.2% cash (realized); 4 sources (news, press_release, sec_filing, transcript); structured_verified
    Charles River repurchased $100 million in shares at approximately $174 per share in the second quarter under the $1 billion stock repurchase authorization approved last October, bringing year-to-date repurchases to $300 million.
  4. Acquisitions and Divestitures · M&A and divestituresPriority 75
    +0.0% assets; 3 sources (news, press_release, sec_filing); 5 forward row(s); structured_verified
    Within Schedule 5, the gain (loss) on divestitures for three months ended June 27, 2026 primarily reflects a $63.7 million loss on the CDMO and Cell Solutions divestiture and a $0.3 million gain on the European Discovery Divestiture.
  5. End-Market Demand Trends · Demand, orders & backlogPriority 74
    +5.0% revenue; 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    DSA backlog as of June 27, 2026: $2.0 billion, increased from $1.9 billion as of December 27, 2025.
  6. Guidance / Outlook · Guidance & outlookPriority 74
    -3.7% revenue; 3 sources (news, press_release, transcript); 17 forward row(s); quote_verified
    The company increased non-GAAP EPS guidance to a range of $11.15 to $11.45 for 2026, representing 8% to 11% year-over-year growth and a $0.25 midpoint increase to prior outlook.
  7. Operating Margin Drivers · Operating income & profitabilityPriority 74
    +14.9% operating_income; 1 forward row(s); structured_verified
    Collective cost savings initiatives expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026.
  8. Operating Margin Drivers · UnclassifiedPriority 74
    +4.6% margin; 2 sources (press_release, transcript); 5 forward row(s); quote_verified
    The company expects operating margin expansion of approximately 120 to 150 basis points in 2026, with Manufacturing and DSA segments driving the year-over-year increase and a clear line of sight into at least 500 basis points of second-half improvement compared to the first half.
  9. Operating Expense Trends · Operating expenses (SG&A)Priority 67
    +0.8% margin; 3 sources (press_release, sec_filing, transcript); 6 forward row(s); quote_verified
    Unallocated corporate costs for the three months ended June 27, 2026: $106,394 thousand, an increase of $35,900 thousand or 50.9% compared to $70,494 thousand in the prior-year period.
  10. Headcount and Restructuring · Restructuring & impairmentPriority 66
    -7.7% operating_income (realized); structured_verified
    Restructuring charges were $99.8 million and $107.0 million during the fiscal years 2025 and 2024, respectively.
  11. Interest Rate and Refinancing Exposure · Interest ratesPriority 64
    quote_verified
    Interest expense for the six months ended June 27, 2026: $57,082 thousand, a decrease of $0.8 million or 1.3% compared to $57,851 thousand in the prior-year period, primarily due to lower average interest rates on revolving credit facility balances; partially offset by non-cash accretion related to the Cambodian acquisition.
  12. Portfolio Refinement and M&A · M&A and divestituresPriority 60
    +4.2% margin (realized); 4 forward row(s); quote_verified
    Divestitures of certain European discovery services sites and the CDMO and Cell Solutions businesses were completed in May 2026 and contributed a partial quarter benefit to a 420 basis point sequential operating margin improvement to 20.5% in the second quarter.

Threads by pillar

Revenue & Demand Priority 88 · 7 threads

Costs & Margins Priority 86 · 5 threads

Capital & Balance Sheet Priority 94 · 5 threads

Strategy & Portfolio Priority 81 · 4 threads

Legal, Regulatory & Policy Priority 55 · 2 threads

Guidance & Outlook Priority 74 · 1 thread

Macro & Market Conditions Priority 73 · 4 threads

Unclassified Priority 82 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
revenue-0.1%+19.3%-3.0%
operating_income+14.6%+15.3%+13.3%
margin+5.3%+10.3%+36.8%
cash+0.3%+0.3%-7.6%
assets+0.0%+0.0%-0.5%
liability-0.0%+0.0%-10.6%
net_income——-38.0%